Rosiglitazone Effects on Cognition for Adults in Later Life

Mild Cognitive Impairment Clinical Trial

— RECALL  

Official title:

The Effects of Rosiglitazone on Cognition in Patients With MCI

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00242593
• Other study ID #: IA0087
• Secondary ID: 1R01AG025502-01A
• Status: Active, not recruiting
• Phase: Phase 2
• First received: October 19, 2005
• Last updated: August 4, 2011
• Start date: June 2006
• Est. completion date: December 2011

Study information

• Verified date: August 2011
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of the insulin-sensitizing medication rosiglitazone on attention and memory skills in older adults with mild cognitive impairment (MCI). The study also will examine the effects of this medication on brain structures that support memory and other thinking abilities, and on biological markers associated with inflammation, insulin resistance, and cardiovascular disease.

Description:

The study will examine the effects of the insulin-sensitizing agent rosiglitazone on learning and memory for 120 patients diagnosed with MCI. Participants will be randomized to an 18-month trial of rosiglitazone or placebo, followed by a 2-month washout period. At screening and at treatment month 18, all participants will undergo an oral glucose tolerance test (OGTT) to estimate pre- and post- treatment insulin sensitivity and β-cell function. Cognitive measures and blood samples for biochemical assays will be obtained at baseline, treatment months 6, 12, and 18, and washout (two months after completing treatment).

During treatment, participants will have safety labs drawn and receive physical assessment of any adverse events, changes in health status, or changes in medication; initially these visits will be done at weeks 2 and 4, and then every three months. For months in which a safety visit is not scheduled, telephone monitoring to assess any health concerns will be conducted.

All participants enrolled in the primary study will be approached to participate in an MRI substudy; patients will undergo serial brain MRI before treatment and following 18 months of rosiglitazone or placebo, using three-dimensional T1-weighted images. Comparison of MCI patients receiving rosiglitazone and placebo will be conducted to determine whether the rate of medial temporal lobe (MTL) and whole brain atrophy is altered following treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 120
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• MCI diagnosis: Participants will be diagnosed with MCI by consensus of a team of physicians and neuropsychologists experienced in the diagnosis of MCI, using the Petersen (Petersen, 1999, 2001) criteria for amnestic MCI or multiple domain MCI with amnestic features: a) the presence of subjective memory complaints, evaluated via detailed patient history and informant interview, b) objective verification of memory impairment as measured by neuropsychological tests, c) normal general cognitive function, d) intact or only mildly impaired activities of daily living, and e) absence of dementia per NINCDS/ADRDA and/or DSM-IV criteria

Exclusion Criteria:

The following exclusion criteria will be used, based on initial physical examination, medical history, lab work, and oral glucose tolerance test (OGTT) results:

• Diagnosis of diabetes or other relevant glucoregulatory disorders

• Use of any oral anti-diabetic compounds

• Clinically significant elevations in liver function

• Significant neurological disease that might affect cognition, other than MCI, including Alzheimer's disease, large-vessel stroke, Parkinson's disease, multiple sclerosis, recent severe head injury (loss of consciousness for more than 30 minutes in the past year), or remote head injury resulting in permanent cognitive or neurological sequelae

• History or current evidence of congestive heart failure (CHF)

• History of documented ischemic cardiac disease, i.e., angina, MI, angioplasty, stent, or CABG

• History of cardiac or vascular surgery, or significant arrhythmia within the last year; or planned major intervention such as cardiac surgery or stenting. A history of cardiac surgery for non-ischemic indications (i.e., valve repair or replacement) greater than one year prior to enrollment is not exclusionary if all other criteria are met

• Significant ECG abnormalities including heart rate less than 50 or greater than 100 beats per minute (dependent upon the individual's general health); any previously unrecognized arrhythmia requiring further intervention

• Significant peripheral edema at the time of screening

• Significant medical illness or organ failure, including but not limited to renal disease, hepatic disease, and unstable cardiac disease

• Regular current use of antipsychotic, anticonvulsive, anxiolytic, or sedative medications; antidepressant medications are not exclusionary, provided the individual does not have current major depression

• A current diagnosis of major depression or other significant psychiatric comorbidity

• Clinically significant anemia at the time of screening

• Fasting triglyceride level greater than 400

• Fasting glucose 125 or greater, or two-hour glucose value greater than 199 during the OGTT; participants will be notified if their fasting blood sugar (monitored every 3 months) exceeds 125, and they will be withdrawn from further participation if their fasting blood sugar exceeds 125 for two consecutive months

• For the MRI substudy, additional exclusion criteria include 1) previous exposure to work involving the cutting or grinding of metal, 2) the presence of a pacemaker, aneurysm clip, or other implanted metal device that would prohibit MRI procedures, and 3) significant history of claustrophobia

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cognition Disorders
• Mild Cognitive Impairment

Intervention

Drug:
• Rosiglitazone
4 mg twice daily oral rosiglitazone or placebo pill for 18 months

Locations

Country	Name	City	State
United States	UCLA Alzheimer's Disease Center	Los Angeles	California
United States	Banner Alzheimer Institute	Phoenix	Arizona
United States	University of Washington/VA Puget Sound Health Care System	Seattle/Tacoma	Washington

Sponsors (3)

Lead Sponsor	Collaborator
University of Washington	GlaxoSmithKline, National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001 Apr 15;21(8):2561-70. — View Citation

Goldstein BJ. Rosiglitazone. Int J Clin Pract. 2000 Jun;54(5):333-7. — View Citation

Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003 Oct;60(10):1394-9. — View Citation

Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med. 2001;52:239-57. Review. — View Citation

Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17(1):27-45. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive measures: delayed list recall, Stroop Interference test		every 6 months for 18 months, again 2 at months post-treatment (20 months)	No
Primary	Biological outcomes: plasma insulin, IDE, AB40, AB42, inflammatory cytokines, and F2-isoprostanes		every 6 months for 18 months, again 2 at months post-treatment (20 months)	No
Primary	MRI outcome: Whole brain and medial temporal lobe atrophy rate		baseline and 18 months	No
Secondary	Cognitive measures: ADAS-cog total score, story recall verbal fluency, paired associate learning, SOPT, rating scales		every 6 months for 18 months, again 2 at months post-treatment (20 months)	No